American Heart Association (AHA) 2017 Scientific Session

Nov. 13, 2017 Event

EP-7041 is a novel, potent, selective small molecule FXIa inhibitor designed to prevent thrombosis with limited risk for bleeding side effects. Results from the Phase 1a/1b study were highlighted in a poster presentation on Nov. 13 at the American Heart Association (AHA) Scientific Sessions 2017, in Anaheim, California.